Skip to main content

ADVERTISEMENT

biomarkers

Patricia K. Coyle, MD, on Fluid and Neurophysiological Biomarkers for the Early Diagnosis of Progression of RRMS to SPMS
Podcasts
08/26/2020
She discusses the current state of evidence on the role of fluid and neurophysiological biomarkers in the early diagnosis of progression of relapsing-remitting MS to secondary progressive MS, and more.
She discusses the current state of evidence on the role of fluid and neurophysiological biomarkers in the early diagnosis of progression of relapsing-remitting MS to secondary progressive MS, and more.
She discusses the current state...
08/26/2020
Neurology
News
05/13/2020
For patients with diffuse large B-cell lymphoma (DLBCL), presence of hypercalcemia at diagnosis correlates with negative prognostic factors and a short diagnosis-to-treatment interval, according to a retrospective...
For patients with diffuse large B-cell lymphoma (DLBCL), presence of hypercalcemia at diagnosis correlates with negative prognostic factors and a short diagnosis-to-treatment interval, according to a retrospective...
For...
05/13/2020
Journal of Clinical Pathways
Blog
11/12/2019
Barbara Aung DPM
Lecturers recently discussed “biomarkers” at the Symposium on Advanced Wound Care Fall (SAWC Fall) 2019 in Las Vegas last month. Attending different lectures, I started to realize that although the term biomarker seems new, biomarkers are...
Lecturers recently discussed “biomarkers” at the Symposium on Advanced Wound Care Fall (SAWC Fall) 2019 in Las Vegas last month. Attending different lectures, I started to realize that although the term biomarker seems new, biomarkers are...
Lecturers recently discussed...
11/12/2019
Podiatry Today
Research Reports
02/15/2018
Casey Mason
Peter G Ellis, MD
Kathy Lokay
Amanda Barry, MPH
Natalie Dickson, MD
Ray Page, DO, PhD
Blase Polite, MD
Ravi Salgia, MD, PhD
Michael Savin, MD
Corey Shamah, MD
Mark A Socinski, MD
Abstract: Despite clear clinical benefit and guideline recommendations for predictive biomarker testing and subsequent first-line targeted therapy treatment in patients with non–small cell lung cancer (NSCLC), there...
Abstract: Despite clear clinical benefit and guideline recommendations for predictive biomarker testing and subsequent first-line targeted therapy treatment in patients with non–small cell lung cancer (NSCLC), there...
...
02/15/2018
Journal of Clinical Pathways
Research in Review
09/14/2016
JCP Editors
A non-invasive liquid biopsy may be more effective at detecting clinically relevant mutations in patients with advanced lung cancer than standard biopsies, according to a study published in the journal Clinical...
A non-invasive liquid biopsy may be more effective at detecting clinically relevant mutations in patients with advanced lung cancer than standard biopsies, according to a study published in the journal Clinical...
A...
09/14/2016
Journal of Clinical Pathways
Research in Review
09/09/2016
JCP Editors
A 24-week observational study found that a combination of the cellular biomarkers—lymphocyte count (LC) and plasmablast frequency—helps identify patients with rheumatoid arthritis (RA) who will not benefit from...
A 24-week observational study found that a combination of the cellular biomarkers—lymphocyte count (LC) and plasmablast frequency—helps identify patients with rheumatoid arthritis (RA) who will not benefit from...
A...
09/09/2016
Journal of Clinical Pathways
Research in Review
06/20/2016
JCP Editors
A study of patients with inoperable non-small cell lung cancer (NSCLC) has found that certain blood biomarkers may have prognostic value and could enhance treatment decision-making for providers.  To...
A study of patients with inoperable non-small cell lung cancer (NSCLC) has found that certain blood biomarkers may have prognostic value and could enhance treatment decision-making for providers.  To...
...
06/20/2016
Journal of Clinical Pathways
Research in Review
12/10/2015
JCP Editors
Researchers have developed a novel prognostic framework using genomic sequencing data to assess risk in patients with acute myeloid leukemia (AML). Their work was presented at the American Society of Hematology (ASH)...
Researchers have developed a novel prognostic framework using genomic sequencing data to assess risk in patients with acute myeloid leukemia (AML). Their work was presented at the American Society of Hematology (ASH)...
...
12/10/2015
Journal of Clinical Pathways
Research in Review
12/08/2015
JCP Editors
New research has identified a biomarker that may help to identify early lung cancer and increase survival. Lung cancer remains the deadliest form of cancer in the United States, killing an estimated 158,000 people a...
New research has identified a biomarker that may help to identify early lung cancer and increase survival. Lung cancer remains the deadliest form of cancer in the United States, killing an estimated 158,000 people a...
New...
12/08/2015
Journal of Clinical Pathways